Andrew M. Waters

3.0k total citations · 1 hit paper
17 papers, 794 citations indexed

About

Andrew M. Waters is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Andrew M. Waters has authored 17 papers receiving a total of 794 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in Andrew M. Waters's work include Pancreatic and Hepatic Oncology Research (3 papers), Cancer-related Molecular Pathways (3 papers) and Biochemical and Molecular Research (2 papers). Andrew M. Waters is often cited by papers focused on Pancreatic and Hepatic Oncology Research (3 papers), Cancer-related Molecular Pathways (3 papers) and Biochemical and Molecular Research (2 papers). Andrew M. Waters collaborates with scholars based in United States and Canada. Andrew M. Waters's co-authors include Channing J. Der, Elisabeth M. Perchellet, Kusum L. Chandra, Rachel Bagni, Adrienne D. Cox, James L. Hartley, Gordon Whiteley, Frank McCormick, Irem Ozkan‐Dagliyan and G. Aaron Hobbs and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Cancer Research.

In The Last Decade

Andrew M. Waters

17 papers receiving 787 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

2017 580 citations Andrew M. Waters, Channing J. Der Cold Spring Harbor Perspectives in Medicine profile →

Peers

Andrew M. Waters

ONCOL

PRM

Wells S. Brown United States

Neil MacLean Canada

Marisa Mariani United States

Manpreet Kalkat Canada

Rosalin Mishra United States

Meagan B. Ryan United States

Grit S. Herter-Sprie United States

Akriti Kharbanda United States

Pranita Atri United States

Vicky Pui‐Chi Tin Hong Kong

Wells S. Brown United States

Andrew M. Waters

552 ×1.3

266 ×0.7

ONCOL

206 ×1.0

139 ×1.6

PRM

89 ×1.1

Citations per year, relative to Andrew M. Waters Andrew M. Waters (= 1×) peers Wells S. Brown

Countries citing papers authored by Andrew M. Waters

Since Specialization

Citations

This map shows the geographic impact of Andrew M. Waters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew M. Waters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew M. Waters more than expected).

Fields of papers citing papers by Andrew M. Waters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew M. Waters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew M. Waters. The network helps show where Andrew M. Waters may publish in the future.

Co-authorship network of co-authors of Andrew M. Waters

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew M. Waters. A scholar is included among the top collaborators of Andrew M. Waters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew M. Waters. Andrew M. Waters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Hammill, Adrienne M., et al.. (2025). RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric Blood & Cancer. 72(5). e31605–e31605. 2 indexed citations

Martz, Colin A., Andrew M. Waters, Alejandro Barrera, et al.. (2024). Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers. npj Precision Oncology. 8(1). 124–124. 3 indexed citations

Ahmad, Syed A., et al.. (2024). Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Frontiers in Oncology. 14. 1402128–1402128. 12 indexed citations

Waters, Andrew M., et al.. (2024). Abstract 1936: KEAP1-NRF2 mediated resistance against KRASG12D inhibitor in pancreatic ductal adenocarcinoma. Cancer Research. 84(6_Supplement). 1936–1936. 1 indexed citations

Drizyte‐Miller, Kristina, Andrew M. Waters, Clint A. Stalnecker, et al.. (2024). Abstract 4588: Combination of MTA-cooperative PRMT5 inhibitor and direct mutant-selective KRAS inhibitors as a novel therapeutic approach for MTAP-deficient pancreatic cancer. Cancer Research. 84(6_Supplement). 4588–4588. 2 indexed citations

Edwards, A. Cole, Clint A. Stalnecker, Jennifer E. Klomp, et al.. (2023). TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors. Cancer Research. 83(24). 4112–4129. 33 indexed citations

Waters, Andrew M., Clint A. Stalnecker, Runying Yang, et al.. (2023). Abstract 1075: Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer. Cancer Research. 83(7_Supplement). 1075–1075. 1 indexed citations

Schaefer, Antje, Craig M. Goodwin, Mariaelena Pierobon, et al.. (2022). Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics. 21(5). 762–774. 10 indexed citations

Goodwin, Craig M., Kirsten L. Bryant, Samuel D. George, et al.. (2020). Abstract B15: CRISPR/Cas9 genetic screen identifies novel therapeutic strategies for treating HRAS mutant HNSCC with farnesyltransferase inhibitors (FTIs). Clinical Cancer Research. 26(12_Supplement_2). B15–B15. 1 indexed citations

10.

Goodwin, Craig M., Andrew M. Waters, Bjoern Papke, et al.. (2019). Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Research. 79(13_Supplement). LB–287. 1 indexed citations

11.

Waters, Andrew M. & Channing J. Der. (2017). KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor Perspectives in Medicine. 8(9). a031435–a031435. 580 indexed citations breakdown →

12.

Waters, Andrew M., Irem Ozkan‐Dagliyan, Angelina V. Vaseva, et al.. (2017). Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science Signaling. 10(498). 43 indexed citations

13.

Waters, Andrew M., et al.. (2016). Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells. PLoS ONE. 11(9). e0163272–e0163272. 11 indexed citations

14.

Ye, Xiaoying, King C. Chan, Andrew M. Waters, et al.. (2016). Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget. 7(52). 86948–86971. 19 indexed citations

15.

Waters, Andrew M., Elisabeth M. Perchellet, Paul D. Thornton, et al.. (2012). Antitumor effects of synthetic 6,7-annulated-4-substituted indole compounds in L1210 leukemic cells in vitro.. PubMed. 32(11). 4671–84. 5 indexed citations

16.

Waters, Andrew M., et al.. (2011). Bioactivity of synthetic 2-halo-3-aryl-4(3H)-quinazoliniminium halides in L1210 leukemia and SK-BR-3 mammary tumor cells in vitro.. PubMed. 31(6). 2083–93. 11 indexed citations

17.

Chandra, Kusum L., et al.. (2010). Synthesis and antiproliferative evaluation of 5-oxo and 5-thio derivatives of 1,4-diaryl tetrazoles. Bioorganic & Medicinal Chemistry Letters. 20(13). 3920–3924. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact